环球印务(002799) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥682,788,022.13, representing a 59.18% increase compared to the same period last year[4] - The net profit attributable to shareholders was ¥23,730,390.74, a decrease of 1.85% year-on-year, while the net profit excluding non-recurring items was ¥20,881,278.03, up 1.43%[4] - The company's operating income increased to CNY 2,639,408,582.41, representing an 88.74% growth compared to the previous period[11] - Total operating revenue for Q3 2021 reached ¥2,307,918,790.20, a significant increase of 80.5% compared to ¥1,275,526,633.30 in Q3 2020[25] - Operating profit for Q3 2021 was ¥136,155,442.35, up 40.3% from ¥97,069,099.80 in the same period last year[26] - Net profit attributable to the parent company for Q3 2021 was ¥101,549,331.34, representing a 54.9% increase from ¥65,570,467.64 in Q3 2020[26] - The total comprehensive income for the period reached ¥118,749,758.29, compared to ¥81,710,268.93 in the previous period, reflecting a significant increase[27] - The net profit attributable to the parent company was ¥101,549,331.34, up from ¥65,570,467.64, indicating a growth of approximately 54.9%[27] - Basic and diluted earnings per share both stood at ¥0.40, compared to ¥0.26 in the previous period, representing a 53.8% increase[27] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,726,182,157.23, reflecting a 15.12% increase from the end of the previous year[5] - Total assets as of September 30, 2021, amounted to ¥1,726,182,157.23, compared to ¥1,499,501,682.56 at the end of 2020, reflecting a growth of 15.1%[23] - Total liabilities increased to ¥889,053,567.44 as of September 30, 2021, from ¥752,787,414.95 at the end of 2020, marking a rise of 18.1%[23] - Current assets totaled ¥1,043,388,343.18, up 17.7% from ¥886,093,307.99 at the end of 2020[22] - Owner's equity totaled CNY 746,714,267.61, with total equity attributable to shareholders at CNY 669,611,645.99[35] Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥46,144,103.80[4] - Cash inflows from operating activities totaled ¥2,650,294,570.86, a substantial rise from ¥1,414,790,818.85, marking an increase of about 87.2%[30] - The net cash flow from operating activities was ¥46,144,103.80, recovering from a negative cash flow of ¥111,360,678.46 in the previous period[30] - Cash received from tax refunds rose by 47.94% to CNY 526,500.00, primarily due to income tax refunds received during the reporting period[11] - Cash outflows for investing activities amounted to ¥107,684,489.87, compared to ¥19,801,637.55 in the previous period, indicating increased investment activity[31] - The ending balance of cash and cash equivalents was ¥257,048,284.26, compared to ¥238,200,718.04 at the end of the previous period, showing a slight increase[31] Investment and Expenses - Research and development expenses rose by 74.21% to ¥41,602,594.76, indicating increased investment in innovation[10] - Research and development expenses for Q3 2021 were ¥41,602,594.76, significantly higher than ¥23,880,225.70 in Q3 2020, indicating a focus on innovation[26] - The investment income for the period was ¥13,990,821.86, a 144.18% increase, reflecting improved performance from equity investments[10] - Investment income received reached CNY 9,019,519.78, attributed to dividend distributions from subsidiaries[11] - The company has increased cash payments for fixed assets and equipment by 619.04% to CNY 88,333,410.36, mainly for land acquisition and key production equipment[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,775, with no preferred shareholders[13] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds a 46.25% stake in the company[13] Future Plans - The company is expanding its production capacity with a new green packaging smart manufacturing industrial park project in Xi'an, signed on March 26, 2021[16] - A non-public offering of A-shares is planned, with a maximum issuance of 68,040,000 shares, representing up to 27% of the total share capital before the issuance[17] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24] Other Information - The company reported a significant increase in accounts receivable by 30.70% to ¥375,325,014.53, attributed to higher revenue[10] - The company experienced a 1410.11% increase in contract liabilities, reaching ¥36,478,596.37, due to increased customer prepayments[10] - Cash flow from financing activities decreased by 48.23% to CNY 103,550,000.00, primarily due to reduced borrowings from Shaanxi Pharmaceutical Group[11] - The report for the third quarter was not audited[38]